Upgrade to SI Premium - Free Trial

UBS Reiterates Buy Rating on Merck (MRK)

April 20, 2026 9:51 AM
UBS analyst Michael Yee reiterated a Buy rating and $145.00 price target on Merck (NYSE: MRK).The analyst commented, "We continue ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments